I-Mab Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (2)

Latest Posts

About This Stock More About This Stock
Week In Review: CANbridge Licenses LogicBio's Adeno-Associated Virus For Gene Therapies In $591 Million Deal
Article By: ChinaBio® Today
Saturday, May 1, 2021 12:51 PM EDT
CANbridge Pharma of Beijing acquired a global license to LogicBio’s adeno-associated virus sL65 in gene therapy candidates for Fabry and Pompe disease treatments. CANbridge will make a $10 million upfront payment for the two candidates.
In this article: JNJ, RVNC, MIRM, LEGN, IMAB
Read
Week In Review: Haohai Bio Enters $527 Million Deal For Dermatology Products
Article By: ChinaBio® Today
Saturday, March 13, 2021 1:02 PM EDT
Shanghai Haohai Biological announced a $527 million agreement to develop Eirion Therapeutics' aesthetic dermatology products in China. Haohai will pay $8 million upfront and make a $32 million investment in Eirion Series A Preferred Stock.
In this article: CASI, SRNE, EXEL, BGNE, IMAB
Read
Week In Review: China Life Science Scores Over $1 Billion In Week's Deals
Article By: ChinaBio® Today
Saturday, February 27, 2021 1:33 PM EDT
New Horizon Health staged a $263 million IPO last week on the Hong Kong Exchange to support its early cancer screening tests. The stock tripled in trading, giving the company a market cap of $4.3 billion.
In this article: IMAB
Read
Week In Review: Suzhou's Adagene Raises $140 Million In US IPO To Develop Oncology Drugs
Article By: ChinaBio® Today
Saturday, February 13, 2021 12:37 PM EDT
Adagene, a Suzhou immunoncology biopharma, completed a $140 million NASDAQ IPO and climbed 56% higher in open market trading. Adagene has a market capitalization of about $1 billion.  
In this article: LLY, MPSYF, ATBPF, IMAB
Read
Week In Review: Junshi Signs $1.1 Billion Deal For US-Canada Rights To PD-1
Article By: ChinaBio® Today
Saturday, February 6, 2021 12:55 PM EDT
Shanghai Junshi Bio out-licensed US-Canada rights for its anti-PD-1 antibody to Coherus Bio​ in an agreement worth up to $1.1 billion. Syapse closed a $68 million growth equity investment led by China's Ally Bridge Group
In this article: LLY, ILMN, CHRS, EXEL, DVAX, IMAB
Read

Latest Tweets for $IMAB

No tweets yet!